⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

October 6, 2025Open Access

Figure 2 from A First-In-Human Dose-Escalation Phase I Study of Basroparib, a Tankyrase Inhibitor, in Patients with Advanced-Stage Solid Tumors

Christopher H. Lieu Heinz‐Josef Lenz Al B. Benson Xue Meng Uk-Il Kim Song Hyun Kim Kyungjin Kim Moo Je Sung

View Full Paper

Ask AI

Bookmark

Share

Key Points

The treatment outcomes indicate stable disease in some patients while others experienced progressing disease.
The study evaluates effects on solid tumors through a dose-escalation approach, focusing on patient responses.
This phase I study emphasizes the safety and tolerability of basroparib, a novel tankyrase inhibitor, in treating advanced tumors.
Patients were monitored over cycles, showing varied disease responses across the enrolled individuals.

Implication

Phase I trial explores basroparib's effects on disease progression in advanced-stage tumor patients, suggesting potential benefits.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Lieu et al. (2025) studied this question.

synapsesocial.com/papers/68e5c1ba6950a706b22b5388 https://doi.org/10.1158/2767-9764.30285016

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Figure 1 from A First-In-Human Dose-Escalation Phase I Study of Basroparib, a Tankyrase Inhibitor, in Patients with Advanced-Stage Solid Tumors2025
2Table 4 from A First-In-Human Dose-Escalation Phase I Study of Basroparib, a Tankyrase Inhibitor, in Patients with Advanced-Stage Solid Tumors2025
3Table 1 from A First-In-Human Dose-Escalation Phase I Study of Basroparib, a Tankyrase Inhibitor, in Patients with Advanced-Stage Solid Tumors2025
4Table 2 from A First-In-Human Dose-Escalation Phase I Study of Basroparib, a Tankyrase Inhibitor, in Patients with Advanced-Stage Solid Tumors2025
5A First-In-Human Dose-Escalation Phase 1 Study of Basroparib (STP1002), a Tankyrase Inhibitor, in Patients with Advanced-Stage Solid Tumors2025 · 5 citations

More related papers

Data from A First-In-Human Dose-Escalation Phase I Study of Basroparib, a Tankyrase Inhibitor, in Patients with Advanced-Stage Solid Tumors2025
Abstract C006: LODESTAR: A Single Arm Phase II Study of Rucaparib in Solid Tumors with Pathogenic Germline or Somatic Variants in Homologous Recombination Repair (HRR) Genes2024
A phase I/II study of talazoparib and axitinib in patients with advanced clear cell renal cell carcinoma.2024